Search
relugolix
Indications:
- androgen-deprivation therapy for prostate cancer
- used in Japan for treatment of uterine fibroids
Dosage:
- loading dose 360 mg PO, then 120 mg PO QD
Monitor:
- serum testosterone
Mechanism of action:
- gonadotropin-releasing hormone antagonist
General
antineoplastic endocrine agent
References
- Nelson R
Relugolix: Novel Drug for ADT in Advanced Prostate Cancer.
Medscape - Jun 01, 2020
https://www.medscape.com/viewarticle/931504
Component-of
estradiol/norethindrone/relugolix